Technical Analysis for REPL - Replimune Group, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
12.2 | -10.56% | -1.44 |
REPL closed down 10.56 percent on Friday, November 15, 2019, on 6.72 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| See historical REPL trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 200 DMA Support | Bullish | -10.56% | |
| Pocket Pivot | Bullish Swing Setup | -10.56% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2019
- Sector: Healthcare
- Industry: Biotechnology
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Solid Tumors Cancer Treatments Virotherapy Experimental Cancer Treatments Transgene Sa
Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Solid Tumors Cancer Treatments Virotherapy Experimental Cancer Treatments Transgene Sa
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more REPL news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 18.25 |
| 52 Week Low | 8.88 |
| Average Volume | 121,926 |
| 200-Day Moving Average | 13.5792 |
| 50-Day Moving Average | 14.2238 |
| 20-Day Moving Average | 15.7865 |
| 10-Day Moving Average | 15.812 |
| Average True Range | 1.2232 |
| ADX | 45.88 |
| +DI | 15.2781 |
| -DI | 29.8017 |
| Chandelier Exit (Long, 3 ATRs ) | 14.0104 |
| Chandelier Exit (Short, 3 ATRs ) | 15.8696 |
| Upper Bollinger Band | 18.5896 |
| Lower Bollinger Band | 12.9834 |
| Percent B (%b) | -0.14 |
| BandWidth | 35.512622 |
| MACD Line | 0.0983 |
| MACD Signal Line | 0.663 |
| MACD Histogram | -0.5647 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 14.47 | ||||
| Resistance 3 (R3) | 14.73 | 14.22 | 14.09 | ||
| Resistance 2 (R2) | 14.22 | 13.64 | 14.09 | 13.97 | |
| Resistance 1 (R1) | 13.21 | 13.28 | 12.96 | 12.96 | 13.84 |
| Pivot Point | 12.71 | 12.71 | 12.58 | 12.58 | 12.71 |
| Support 1 (S1) | 11.70 | 12.13 | 11.44 | 11.44 | 10.56 |
| Support 2 (S2) | 11.19 | 11.77 | 11.06 | 10.43 | |
| Support 3 (S3) | 10.18 | 11.19 | 10.31 | ||
| Support 4 (S4) | 9.93 |
